Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1794783/000179478323000099/slqt-20230630.htm
September 2023
May 2023
March 2023
March 2023
February 2023
February 2023
January 2023
December 2022
November 2022
November 2022
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1794783/000179478323000099/slqt-20230630.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Selectquote, Inc..
Selectquote, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Rating
Learn More![]()
Adjusted EBITDA by Segment 2023 compared to 2022--Adjusted EBITDA from our Senior segment was $155.1 million for the year ended June 30, 2023, a $316.8 million, or 196%, increase compared to Adjusted EBITDA of $(161.7) million for the year ended June 30, 2022.
Interest Expense, Net The following table presents our interest expense, net for the years ended June 30 and the percentage changes from the prior year: 2023 compared to 2022-Interest expense increased $37.0 million, or 85%, in 2023 compared to 2022, as a result of interest incurred on the Term Loans due to additional principal outstanding and changes under the Fourth Amendment, the amortization and write-off of additional deferred financing costs associated with the amendments to the Senior Secured Credit Facility, as well as higher interest rates during the period.
2022 compared to 2021-Selling, general, and administrative expenses increased $26.7 million, or 42%, in 2022 compared to 2021, primarily due to $13.7 million in higher compensation costs due to additional headcount to support the growth in the business; $4.3 million in depreciation and amortization expenses due to additional fixed assets and software in service; $4.5 million in professional services fees due to increases in recruiting, accounting and legal, and insurance costs; and $3.1 million of charges related to the impairment of long-lived intangible assets as described in Note 7 to the consolidated financial statements.
2022 compared to 2021-Interest expense increased $14.3 million, or 49%, in 2022 compared to 2021, primarily as a result of the increase in our outstanding balances on the Term Loans and DDTL Facility, amortization of additional deferred financing costs associated with the amendments to the Senior Secured Credit Facility, and the ticking fee interest assessed on the remaining available borrowing capacity of the DDTL Facility.
On April 30, 2021, we acquired 100% of the outstanding shares of Express Med Pharmaceuticals for an aggregate purchase price of up to $24.0 million (subject to customary adjustments), comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any.
Adjustments for non-cash items primarily...Read more
The decrease in Adjusted EBITDA...Read more
The higher our retention rates,...Read more
2022 compared to 2021-Income tax...Read more
Non-GAAP Financial Measures To supplement...Read more
See "Management's Discussion and Analysis...Read more
The following table presents our...Read more
The Company recognizes revenue when...Read more
The cash decrease resulting from...Read more
Adjusted EBITDA from Healthcare Services...Read more
The following table presents our...Read more
The decrease in Adjusted EBITDA...Read more
2022 compared to 2021-Technical development...Read more
It also includes shipping, supplies,...Read more
These limitations include the fact...Read more
We apply the following five-step...Read more
Our proprietary technology allows us...Read more
Such costs primarily consist of...Read more
Adjusted EBITDA from our Life...Read more
Our platform provides unbiased comparison...Read more
The decrease in operating costs...Read more
Adjusted EBITDA from Healthcare Services...Read more
The decrease in Adjusted EBITDA...Read more
The degree to which we...Read more
Other costs consist of compensation...Read more
Total costs per policy increased...Read more
The $46.9 million increase in...Read more
Auto & Home-Commission revenue is...Read more
The following tables reconcile Adjusted...Read more
The increase in Adjusted EBITDA...Read more
Adjusted EBITDA from our Auto...Read more
Adjusted EBITDA from our Auto...Read more
For the year ended June...Read more
Revenue from our Life segment...Read more
We monitor our acquisition costs...Read more
The $180.1 million increase in...Read more
Revenues generated from SelectRx are...Read more
Acquisitions On February 1, 2021,...Read more
For the year ended June...Read more
For the year ended June...Read more
Adjusted EBITDA is calculated as...Read more
Of this, Medicare Advantage plans...Read more
2023 compared to 2022-Total revenue...Read more
These non-GAAP financial measures are...Read more
In particular, we believe that...Read more
We regularly assess these estimates;...Read more
Adjusted EBITDA from our Life...Read more
Year Ended June 30, 2021-Net...Read more
2022 compared to 2021-Cost of...Read more
The increase was partially offset...Read more
Population Health helps members understand...Read more
Revenue from Healthcare Services was...Read more
Revenue from Healthcare Services was...Read more
For Senior, excluding the $193.3...Read more
Technical Development Technical development expenses...Read more
2022 compared to 2021-Commission revenue...Read more
The cash decrease resulting from...Read more
The estimated attainment of performance-based...Read more
However, we've seen an increase...Read more
Effective for policies sold during...Read more
Commission Revenue Recognition and Commissions...Read more
During the year ended June...Read more
The current portion of commissions...Read more
The following table depicts the...Read more
Revenue from Population Health is...Read more
Cohort adjustments can be positive...Read more
We represent approximately 25 leading,...Read more
Industry growth is driven by...Read more
Industry growth is driven by...Read more
Changes in key assumptions could...Read more
Revenue is recognized at different...Read more
Our insurance distribution business, which...Read more
Recent Accounting Pronouncements For a...Read more
The U.S. life insurance market...Read more
Our platform then captures and...Read more
The additions of SelectRx and...Read more
Revenue from our Life segment...Read more
Effective July 1, 2022, as...Read more
Production bonus revenue increased $18.4...Read more
The decrease was primarily due...Read more
Income Tax Expense (Benefit) The...Read more
Based on our financial projections,...Read more
Technological innovations, including the development...Read more
We have also developed proprietary...Read more
Year Ended June 30, 2022-Net...Read more
The number of average productive...Read more
Based on the seasonality of...Read more
Final expense premiums decreased 29%...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Selectquote, Inc. provided additional information to their SEC Filing as exhibits
Ticker: SLQT
CIK: 1794783
Form Type: 10-K Annual Report
Accession Number: 0001794783-23-000099
Submitted to the SEC: Wed Sep 13 2023 4:02:19 PM EST
Accepted by the SEC: Wed Sep 13 2023
Period: Friday, June 30, 2023
Industry: Insurance Agents Brokers And Service